Innogenetics, Abbott Strike $9.5M Deal On HCV Patent

Law360, New York (April 14, 2008, 12:00 AM EDT) -- Innogenetics NV has struck a $9.5 million settlement and licensing agreement with Abbott Laboratories that resolves a long-standing patent dispute between the two companies over hepatitis C virus testing, the Belgian biotech firm announced Monday.

Gent, Belgium-based Innogenetics said the agreement would grant Abbott a nonexclusive license to sell hepatitis C virus genotyping products based on real-time technologies. In exchange, Innogenetics will receive royalties for each hepatitis C test that Abbott sells worldwide during the patent term.

Abbott will also receive access to key Innogenetics patents...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.